Inmune Bio Stock Today
| INMB Stock | USD 5.05 0.16 3.27% |
Performance0 of 100
| Odds Of DistressLess than 30
|
INmune Bio is trading at 5.05 as of the 1st of December 2024, a 3.27 percent increase since the beginning of the trading day. The stock's open price was 4.89. INmune Bio has about a 30 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for INmune Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of June 2024 and ending today, the 1st of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of February 2019 | Category Healthcare | Classification Health Care |
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 22.17 M outstanding shares of which 3.57 M shares are currently shorted by private and institutional investors with about 14.96 trading days to cover. More on INmune Bio
Moving against INmune Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
INmune Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsINmune Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand INmune Bio's financial leverage. It provides some insight into what part of INmune Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
INmune Bio (INMB) is traded on NASDAQ Exchange in USA. It is located in 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432 and employs 11 people. INmune Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 111.97 M. INmune Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 22.17 M outstanding shares of which 3.57 M shares are currently shorted by private and institutional investors with about 14.96 trading days to cover.
INmune Bio currently holds about 61.21 M in cash with (11.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41.
Check INmune Bio Probability Of Bankruptcy
Ownership AllocationINmune Bio has a total of 22.17 Million outstanding shares. INmune Bio secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check INmune Ownership Details
INmune Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Renaissance Technologies Corp | 2024-09-30 | 107.2 K | |
| Northern Trust Corp | 2024-09-30 | 96.8 K | |
| Millennium Management Llc | 2024-06-30 | 92.7 K | |
| Corton Capital Inc. | 2024-09-30 | 76.1 K | |
| Royal Bank Of Canada | 2024-06-30 | 62.6 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 58.6 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 56.8 K | |
| Xtx Topco Ltd | 2024-09-30 | 46.3 K | |
| Citadel Advisors Llc | 2024-09-30 | 46.1 K | |
| Blackrock Inc | 2024-06-30 | 812.9 K | |
| Praetorian Pr Llc | 2024-09-30 | 780.8 K |
INmune Bio Historical Income Statement
INmune Stock Against Markets
INmune Bio Corporate Management
| Christopher Barnum | Head Neuroscience | Profile | |
| BSc FRCPath | Chief Officer | Profile | |
| Raymond MD | President, CoFounder | Profile | |
| Joshua Esq | General Counsel | Profile | |
| David MBA | Treasurer CFO | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Revenue Per Share 0.002 | Quarterly Revenue Growth (0.63) | Return On Assets (0.45) | Return On Equity (0.99) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.